Strides Pharma Science Ltd
STARStrides Pharma Science Ltd
STAR
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -19.59 | 2.06 | 0.30% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.48 | 5.11 | 0.70% |
Forecast & Ratings
Detailed Forecastfrom 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,099.43 | 2,961.59 | 3,097.80 | 3,534.85 | 2,545.66 | 2,909.44 | 3,518.84 | 3,259.23 | 3,935.44 | 3,920.02 | ||||||||||
Raw Materials | 574.64 | 1,612.38 | 1,432.25 | 1,286.65 | 1,189.20 | 1,167.29 | 1,686.50 | 1,407.04 | 1,629.55 | 3,626.50 | ||||||||||
| Power & Fuel Cost | 16.02 | 77.18 | 33.87 | 51.33 | 54.39 | 64.49 | 64.58 | 71.54 | 85.82 | |||||||||||
| Employee Cost | 172.06 | 357.70 | 419.16 | 434.05 | 329.44 | 442.56 | 550.15 | 646.91 | 732.02 | |||||||||||
| Selling & Administrative Expenses | 144.68 | 323.35 | 339.47 | 409.34 | 276.20 | 338.51 | 473.78 | 577.98 | 526.31 | |||||||||||
| Operating & Other expenses | 88.55 | 154.11 | 54.45 | 313.14 | 196.74 | 525.25 | 98.10 | 798.52 | 724.97 | |||||||||||
EBITDA | 1,103.48 | 436.87 | 818.60 | 1,040.34 | 499.69 | 371.34 | 645.73 | -242.76 | 236.77 | 293.52 | ||||||||||
| Depreciation/Amortization | 64.03 | 131.25 | 126.15 | 154.04 | 117.39 | 173.70 | 206.29 | 233.01 | 243.25 | 240.85 | ||||||||||
| PBIT | 1,039.45 | 305.62 | 692.45 | 886.30 | 382.30 | 197.64 | 439.44 | -475.77 | -6.48 | 52.67 | ||||||||||
| Interest & Other Items | 47.44 | 168.17 | 183.10 | 196.24 | 79.29 | 155.72 | 150.07 | 176.74 | 261.14 | 293.97 | ||||||||||
| PBT | 992.01 | 137.45 | 509.35 | 690.06 | 303.01 | 41.92 | 289.37 | -652.51 | -267.62 | -241.30 | ||||||||||
| Taxes & Other Items | 147.01 | 28.92 | 109.60 | 25.55 | -21.60 | 5.53 | 20.94 | -192.30 | -65.00 | -13.28 | ||||||||||
| Net Income | 845.00 | 108.53 | 399.75 | 664.51 | 324.61 | 36.39 | 268.43 | -460.21 | -202.62 | -228.02 | ||||||||||
| EPS | 137.23 | 14.10 | 43.28 | 71.89 | 35.67 | 4.06 | 29.95 | -51.29 | -22.50 | -25.25 | ||||||||||
| DPS | 104.52 | 4.84 | 4.36 | 1.94 | 3.00 | 14.00 | 2.50 | 0.00 | 1.50 | 1.50 | ||||||||||
| Payout ratio | 0.76 | 0.34 | 0.10 | 0.03 | 0.08 | 3.45 | 0.08 | 0.00 | — | -0.06 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Strides Pharma Science Ltd | -22.05 | 2.06 | 0.30% |
| Sun Pharmaceutical Industries Ltd | 35.09 | 5.01 | 0.93% |
| Cipla Ltd | 35.23 | 4.16 | 0.69% |
| Dr Reddy's Laboratories Ltd | 21.37 | 4.14 | 0.69% |
Price Comparison
Compare STAR with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.88%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Strides Pharma Science Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.2495% | Percentage of the fund’s portfolio invested in the stock 0.80% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 37/74 (+1) |
SBI Long Term Equity Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.3677% | Percentage of the fund’s portfolio invested in the stock 0.61% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/72 (0) |
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.2332% | Percentage of the fund’s portfolio invested in the stock 1.05% | Change in the portfolio weight of the stock over the last 3 months -0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/125 (-6) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateJul 24, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Jul 24, 2020
Cash Dividend
Ex DateEx DateAug 22, 2019
Dividend/Share
₹12.00
Ex DateEx Date
Aug 22, 2019
Cash Dividend
Ex DateEx DateJul 19, 2019
Dividend/Share
₹3.00
Ex DateEx Date
Jul 19, 2019
News & Opinions
Strides Pharma To Spin Off Contract Manufacturing Unit Into Stelis Biopharma
2 months ago•Bloomberg Quint
Strides Pharma Shares Hit 52-Week High As USFDA Tentative Nod To HIV Treatment Drug - News18
2 months ago•News18
Strides Pharma Standalone June 2023 Net Sales at Rs 475.32 crore, up 12.32% Y-o-Y
4 months ago•Moneycontrol
Strides Pharma Consolidated June 2023 Net Sales at Rs 929.99 crore, down 1.07% Y-o-Y
4 months ago•Moneycontrol
Strides Pharma sinks after subsidiary plans to divest manufacturing plant
5 months ago•Moneycontrol
Stocks that will see action today (July 5)
5 months ago•The Hindu Businessline
Strides sells arm’s manufacturing unit to Syngene International for Rs 702 crore
5 months ago•Economic Times
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 2.17%, vs industry avg of 8.45%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.74% to 1.23%